(:MLNT)

Jun 24, 2020 04:02 pm ET
Melinta Therapeutics Announces Termination of Merger Agreement and Tender Offer for Shares of Tetraphase
Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage antibiotics company, announced that on June 24, 2020, pursuant to the Agreement and Plan of Merger by and among Melinta, Toronto Transaction Corp. (“Purchaser”) and Tetraphase...
Jun 09, 2020 04:02 pm ET
Melinta Therapeutics Enters Into Agreement to Acquire Tetraphase Pharmaceuticals
Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage antibiotics company, announced that on June 4, 2020, it entered into a definitive merger agreement with Tetraphase Pharmaceuticals, Inc. (“Tetraphase”) pursuant to which Melinta would...
Mar 04, 2020 04:03 pm ET
Melinta Therapeutics Confirms Deerfield as Successful Bidder for Company
Melinta Therapeutics, Inc. (the “Company” or “Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, confirmed today that the Company’s agreement with funds...
Feb 13, 2020 04:02 pm ET
Melinta Therapeutics Announces Court Approval of Chapter 11 Bidding Procedures
Melinta Therapeutics, Inc. (the “Company” or “Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that on February 11, 2020, the United...
Dec 27, 2019 09:02 am ET
Melinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility
Melinta Therapeutics, Inc. (NASDAQ: MLNT) (the “Company” or “Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that it has entered into...
Nov 12, 2019 05:07 pm ET
Melinta Therapeutics Files Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2019
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that it has filed its quarterly report on Form 10-Q...
Oct 24, 2019 04:02 pm ET
Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced the U.S. Food and Drug Administration (FDA) has...
Oct 01, 2019 10:07 am ET
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019
WASHINGTON, Oct. 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that eleven of its member companies will present data from their clinical and research programs at IDWeek 2019 to be held October 2-6, 2019 in Washington D.C.
Sep 03, 2019 04:05 pm ET
Melinta Therapeutics Announces Appointment of Jennifer Sanfilippo to Interim Chief Executive Officer and Director
Melinta Therapeutics, Inc. (Nasdaq: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that Jennifer Sanfilippo has been named interim chief...
Aug 09, 2019 07:31 am ET
Melinta Therapeutics Names David Gill as Chairman and Announces CEO Succession Plan
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced changes to its board of directors and executive...
Aug 09, 2019 07:30 am ET
Melinta Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today reported financial results and provided a business update for the second quarter...
Aug 06, 2019 05:04 pm ET
Melinta Therapeutics Announces Rescheduling of Second Quarter 2019 Financial Results Reporting
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that it will report its second quarter 2019 financial...
Jul 16, 2019 07:30 am ET
Melinta Therapeutics Announces Preliminary Second Quarter 2019 Financial Results and Provides Corporate Update
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today reported preliminary and unaudited financial results and...
Jul 01, 2019 09:13 am ET
X-Biotix Therapeutics Joins Antimicrobials Working Group
WASHINGTON, July 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of X-Biotix Therapeutics, Inc. (X-Biotix) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG's membership to 14 antimicrobial drug companies.
Jun 19, 2019 07:30 am ET
Melinta Therapeutics Announces U.S. FDA Acceptance of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced the U.S. Food and Drug Administration (FDA) has...
May 09, 2019 04:00 pm ET
Melinta Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company, developing and commercializing novel antibiotics to treat serious bacterial infections, today reported financial results and provided a business update for the first quarter...
May 07, 2019 07:30 am ET
Melinta Therapeutics to Present at Making a Difference in Infectious Diseases (MAD-ID) 2019 Annual Meeting
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, announced today that it will present data on its portfolio, including...
May 02, 2019 04:30 pm ET
Melinta Therapeutics to Report First Quarter 2019 Financial Results on May 9, 2019
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced it intends to release its first quarter 2019...
Apr 19, 2019 07:10 am ET
New Research: Key Drivers of Growth for Conatus Pharmaceuticals, MasTec, Cyclacel Pharmaceuticals, Melinta Therapeutics, North American Construction Group, and B.O.S. Better Online Solutions — Factors
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), MasTec, Inc. (NYSE:MTZ),...
Apr 12, 2019 10:08 am ET
Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
WASHINGTON, April 12, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that twelve of its member companies will present data from their clinical and research programs at the 29th annual meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2019) to be held April 13 - 16 in Amsterdam, Netherlands.  
Apr 08, 2019 07:30 am ET
Melinta Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that researchers are scheduled to present multiple...
Mar 13, 2019 04:00 pm ET
Melinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company, developing and commercializing novel antibiotics to treat serious bacterial infections, today reported financial results and provided a business update for the fourth quarter...
Mar 05, 2019 08:00 am ET
Melinta Therapeutics to Report Fourth Quarter and Year-End 2018 Financial Results on March 13, 2019
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced it intends to release its fourth quarter and year-end...
Feb 25, 2019 08:15 am ET
Melinta Therapeutics Announces Closing of Initial $75 Million Vatera Convertible Loan Funding
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced the closing and receipt of the initial $75 million...
Feb 21, 2019 01:30 pm ET
Melinta Therapeutics Announces One-for-Five Reverse Stock Split
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that its Board of Directors has approved a...
Feb 04, 2019 08:00 am ET
Melinta Therapeutics Provides Corporate Updates
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today provided an update on its strategic repositioning initiatives,...
Jan 17, 2019 09:00 am ET
Antimicrobials Working Group Announces Updates to Leadership Team
WASHINGTON, Jan. 17, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the appointment of a new Chairman, Evan Loh, M.D., President, Chief Operating Officer and Chief Medical Officer of Paratek Pharmaceuticals, Inc. Dr. Loh replaces Jeffrey Stein, Ph.D., President and Chief Executive Officer of Cidara Therapeutics, whose two-year term as Chairman of AWG has expired. Dr. Stein will remain on the AWG Executive Committee. The AWG also announced that Ciara Kennedy, Ph.D., President and Chief Executive Officer of Amplyx Pharmaceuticals, Inc. has been appointed as Vice Ch
Dec 19, 2018 08:31 am ET
John H. Johnson Agrees to Become Permanent Chief Executive Officer of Melinta Therapeutics
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that John H. Johnson has agreed to become the permanent chief executive...
Dec 19, 2018 08:30 am ET
Melinta Therapeutics Announces Commitment for New Credit Facility of Up to $135 Million
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that it has received a commitment from Vatera Healthcare Partners LLC and...
Dec 17, 2018 07:30 am ET
Dova Pharmaceuticals Announces Management Changes
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, today announces that David Zaccardelli, Pharm. D., has been...
Nov 30, 2018 10:43 am ET
INVESTIGATION NOTICE:  Kaskela Law LLC Announces Investigation of Melinta Therapeutics, Inc. on Behalf of Stockholders – MLNT
Kaskela Law LLC is investigating Melinta Therapeutics, Inc. (“Melinta” or the “Company”) (NASDAQ: MLNT) on behalf of stockholders.  The investigation seeks to determine whether members of Melinta’s board of directors breached their fiduciary...
Nov 27, 2018 08:00 am ET
Melinta Therapeutics Granted European Commission Marketing Authorization for Vabomere® (meropenem and vaborbactam)
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that the European Commission (EC) has approved Vabomere® (meropenem and...
Nov 26, 2018 05:57 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Board of Directors of Melinta Therapeutics, Inc.  
Levi & Korsinsky announces it has commenced an investigation of Melinta Therapeutics, Inc. (NASDAQGS: MLNT) concerning possible breaches of fiduciary duty. To obtain additional information, go to: http://www.zlkdocs.com/MLNT-Info-Request-Form-7162...
Nov 16, 2018 07:45 am ET
New Research: Key Drivers of Growth for Fresh Del Monte Produce, Liquidity Services, B.O.S. Better Online Solutions, ePlus inc, Pluralsight, and Melinta Therapeutics — Factors of Influence, Major Init
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fresh Del Monte Produce, Inc. (NYSE:FDP), Liquidity Services, Inc....
Nov 07, 2018 07:00 am ET
Melinta Therapeutics Reports Third Quarter 2018 Financial Results
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company, developing and commercializing novel antibiotics to treat serious bacterial infections, today reported financial results and provided a business update for the quarter ended...
Oct 31, 2018 04:05 pm ET
Melinta Therapeutics Announces Appointment of Bruce L. Downey to Board of Directors
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that the company has appointed Bruce L. Downey to its Board...
Oct 29, 2018 08:00 am ET
Melinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABP
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced positive top-line results from its Phase III trial of...
Oct 26, 2018 08:00 am ET
Melinta Therapeutics to Report Third Quarter 2018 Financial Results on November 7, 2018
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced it intends to release its third quarter 2018 financial...
Oct 22, 2018 08:00 am ET
Melinta Therapeutics Announces Appointment of John H. Johnson as Interim Chief Executive Officer
Melinta Therapeutics, Inc., (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, announced today that its board of directors has appointed John H. Johnson as...
Oct 05, 2018 08:00 am ET
Melinta Therapeutics Publishes Findings from Orbactiv® (oritavancin) Real-World Registry Demonstrating Efficacy and Safety Consistent with Phase 3 SOLO Program
Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, announced today that findings from the first phase of the ongoing Clinical and...
Oct 03, 2018 09:14 am ET
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2018
WASHINGTON, Oct. 3, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, announced today that 16 of its member companies will present data from their clinical and research programs at IDWeek 2018 to be held October 3-7 in San Francisco. AWG members are presenting a total of 40 poster presentations, four oral abstract presentations and four features within the symposium entitled "Exploring the Antibiotic Pipeline 2018."
Oct 02, 2018 08:00 am ET
Melinta Therapeutics Publishes Complete Results from Phase III TANGO 2 Study of Vabomere™ (meropenem and vaborbactam)
Data used by CMS in decision to grant a new technology add-on payment (NTAP) for Vabomere, effective Oct. 1, 2018 - NEW HAVEN, Conn., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company...
Oct 01, 2018 08:15 am ET
Melinta Therapeutics and Menarini Group Enter Commercial Agreement for Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) for Injection in 68 Countries
Expands on existing commercial and co-development agreement for Baxdela® (delafloxacin) - NEW HAVEN, Conn. and FLORENCE, Italy, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering,...
Sep 25, 2018 08:00 am ET
Melinta Therapeutics to Present at Upcoming Investor Conferences
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that Dan Wechsler, President and CEO of Melinta, will present...
Sep 24, 2018 08:00 am ET
Melinta Therapeutics to Give New Presentations on Antibiotics Portfolio and Pipeline at IDWeek™ 2018
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that eight presentations and posters highlighting results...
Sep 21, 2018 07:37 am ET
Melinta Therapeutics Receives Positive CHMP Opinion for Vabomere™ (meropenem and vaborbactam)
Hospital-acquired pneumonia including ventilator associated pneumonia (HAP/VAP) – Bacteraemia that occurs in association with any of these infections -Infections due to aerobic Gram-negative organisms where treatment options are limited- NEW HAVEN,...
Sep 18, 2018 08:00 am ET
Melinta Therapeutics Names Peter Milligan as Chief Financial Officer
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that the company has appointed Peter Milligan as its new...
Sep 06, 2018 08:00 am ET
Melinta Therapeutics to Host Meetings at the Morgan Stanley 16th Annual Global Healthcare Conference
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that the company will be attending and hosting meetings at...
Aug 29, 2018 08:00 am ET
Melinta Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that Dan Wechsler, President and CEO of Melinta, will present...
Aug 07, 2018 07:00 am ET
Melinta Therapeutics Reports Second Quarter 2018 Financial Results
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today reported financial results and provided an update on commercial...
Aug 03, 2018 01:31 pm ET
Melinta Therapeutics Announces Vabomere™ (meropenem and vaborbactam) Granted New Technology Add-On Payment by CMS
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that the Centers for Medicare Medicaid Services (CMS) has...
Jul 11, 2018 08:00 am ET
Melinta Therapeutics to Report Second Quarter 2018 Financial Results on August 7, 2018
Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced it intends to release its second quarter 2018 financial...
Jun 13, 2018 04:05 pm ET
Melinta Therapeutics to Present at the JMP Securities Life Sciences Conference
Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that Dan Wechsler, President and CEO of Melinta, will present...
Jun 06, 2018 10:08 am ET
Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018
WASHINGTON, June 6, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that 13 of its member companies will present data from their clinical and research programs at the American Society for Microbiology's ASM Microbe 2018 meeting to be held June 7-11 in Atlanta, GA.
May 31, 2018 08:00 am ET
Melinta Therapeutics Demonstrates Breadth of Commercial and Clinical Programs with 20 Presentations at ASM Microbe 2018
Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that 20 presentations are planned at the American Society for...
May 29, 2018 04:05 pm ET
Melinta Therapeutics Announces Closing of Underwritten Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock
Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that the underwriters of its recently announced public...
May 24, 2018 08:00 am ET
Melinta Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that Dan Wechsler, Melinta’s president and CEO, will present...
May 23, 2018 09:07 pm ET
Melinta Therapeutics Announces Pricing of Public Offering of Common Stock
Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced the pricing of an underwritten public offering of 22,000,000...
May 21, 2018 04:10 pm ET
Melinta Therapeutics Announces Proposed Offering of Common Stock
Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that it has commenced an underwritten public offering of...
May 11, 2018 08:00 am ET
Melinta Therapeutics Launches New Antibiotic Stewardship Program to Combat Growing Threat of Antimicrobial Resistance
Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced the launch of a new antibiotic stewardship program designed to...
May 08, 2018 04:01 pm ET
Melinta Therapeutics Reports First Quarter 2018 Financial Results
Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today reported financial results and provided an update on commercial...
May 08, 2018 08:00 am ET
Melinta Therapeutics to Highlight Commitment to Antibiotics and Product Portfolio at MAD-ID 2018 Annual Meeting
Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced a significant corporate presence at the upcoming Making a...
May 07, 2018 07:00 am ET
Melinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance Clinical Development of a Novel Antimicrobial to Combat Antibiotic-Resistant Bacteria
Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that it has entered into a partnership with CARB-X, under...
Apr 27, 2018 04:15 pm ET
Melinta Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018
NEW HAVEN, Conn., April 27, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced it intends to release its first quarter 2018 financial...
Apr 23, 2018 08:00 am ET
Melinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in Vulnerable Patient Populations
NEW HAVEN, Conn., April 23, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, has presented detailed results from the VABOMERE™ (meropenem and vaborbactam) Phase...
Apr 23, 2018 07:30 am ET
Melinta Therapeutics Presents Updates on the Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens at ECCMID 2018
NEW HAVEN, Conn., April 23, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, presented findings at the European Congress of Clinical Microbiology and Infectious...
Apr 20, 2018 10:17 am ET
Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
WASHINGTON, April 20, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that thirteen of its member companies will present data from their clinical and research programs at the annual meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018) to be held April 21 - 24 in Madrid, Spain.
Apr 16, 2018 08:00 am ET
Melinta Therapeutics to Present Detailed Results from Vabomere TANGO II Trial as well as New In Vitro and In Vivo Findings from Baxdela and Pyrrolocytosine Candidate at ECCMID 2018
NEW HAVEN, Conn., April 16, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that a total of 12 presentations are planned at...
Mar 14, 2018 08:00 am ET
Melinta Therapeutics to Present at Needham & Company’s 17th Annual Healthcare Conference
NEW HAVEN, Conn., March 14, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, announced today that Dan Wechsler, President and CEO of Melinta, will be...
Mar 13, 2018 04:35 pm ET
Melinta Therapeutics Cancels Presentation at The Cowen & Company 38th Annual Health Care Conference Due to Inclement Weather
NEW HAVEN, Conn., March 13, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, announced today that it has cancelled its presentation at the Cowen &...
Mar 13, 2018 07:00 am ET
Melinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
Baxdela™(delafloxacin) Launched February 6, 2018, in U.S. for Adults with ABSSSI
Mar 08, 2018 07:00 am ET
Melinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in Europe
NEW HAVEN, Conn., March 08, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that The Menarini Group, Melinta’s commercial and co-development partner, has...
Mar 02, 2018 07:00 am ET
Melinta Therapeutics to Present at The Cowen and Company 38th Annual Health Care Conference
NEW HAVEN, Conn., March 02, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage pharmaceutical company developing and commercializing novel antibiotics to treat serious bacterial infections, announced today that its president and CEO, Dan Wechsler, will be...
Feb 28, 2018 07:00 am ET
Melinta Therapeutics To Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018
NEW HAVEN, Conn., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, announced today it intends to release its fourth quarter and full year...
Feb 27, 2018 04:05 pm ET
Feb 20, 2018 07:00 am ET
Jan 29, 2018 07:00 am ET
Melinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the United States
– Approved for adult patients with acute bacterial skin and skin structure infections (ABSSSI) –
Jan 18, 2018 07:00 am ET
Jan 08, 2018 07:00 am ET
Melinta Therapeutics Completes Acquisition of The Medicines Company’s Infectious Disease Portfolio
— Expands portfolio to four marketed antibiotics, with peak sales potential over $1 billion —— Creates premier commercial stage global antibiotic franchise with the addition of Vabomere™(meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection —— Melinta’s FDA approved drug...
Jan 08, 2018 07:00 am ET
The Medicines Company Announces Closing of Divestiture of Infectious Disease Business Unit to Melinta Therapeutics
The Medicines Company (NASDAQ:MDCO) today announced the closing of the sale of its infectious disease business unit to Melinta Therapeutics, Inc. (NASDAQ: MLNT) for consideration consisting of $215 million of guaranteed cash, approximately 3.3 million shares of Melinta common stock, tiered royalty payments of 5% to 25% on worldwide net sales of Vabomere™, Orbactiv® and Minocin® IV, and the assumption by Melinta of all royalty, milestone and other payment obligations relating to those products.
Jan 03, 2018 07:00 am ET
Melinta Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference
NEW HAVEN, Conn., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that Dan Wechsler, President and Chief Executive Officer, will be presenting...
Jan 02, 2018 07:00 am ET
Melinta Therapeutics Appoints Lisa DeFrancesco as Senior Vice President of Investor Relations
NEW HAVEN, Conn., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing, and commercializing novel antibiotics to treat serious bacterial infections, today announced the appointment of Lisa DeFrancesco as senior vice president...
Nov 29, 2017 07:00 am ET
Melinta Therapeutics Enters Into Agreement to Acquire Infectious Disease Business from The Medicines Company
- Acquisition positions Melinta as durable and focused pure-play antibiotics company with four marketed products: Baxdela®, Vabomere®, Orbactiv®, and Minocin IV® -
Nov 29, 2017 07:00 am ET
The Medicines Company Announces Definitive Agreement to Sell its Infectious Disease Business Unit to Melinta Therapeutics
The Medicines Company (NASDAQ: MDCO) today announced that it has entered into a definitive agreement to sell its infectious disease business unit to Melinta Therapeutics, Inc. (NASDAQ: MLNT) for $270 million in upfront consideration and guaranteed payments ($215 million of guaranteed cash and $55 million of Melinta common stock), tiered royalty payments of 5% to 25% on worldwide net sales of Vabomere™, Orbactiv® and Minocin IV, and the assumption by Melinta of all royalty, milestone and other payment obligations relating to those products.
Nov 29, 2017 06:12 am ET
Deerfield Supports Melinta Therapeutics Acquisition of The Medicines Company's Infectious Disease Business with a $240 million Commitment to Melinta and a $100 million Commitment to The Medicines Comp
NEW YORK, Nov. 29, 2017 /PRNewswire/ -- Deerfield Management Company announced today it has committed to provide up to $240 million in debt and equity financing to Melinta Therapeutics (NASDAQ: MLNT) and up to $100 million in debt financing to The Medicines Company (NASDAQ: MDCO) in connection with Melinta's acquisition of the infectious disease business from The Medicines Company. The acquisition includes the purchase of global rights for Vabomere, Orbactiv and Minocin IV and the business unit supporting those products.
Nov 13, 2017 07:00 am ET
Melinta Therapeutics Reports First Patient Treated in Phase 2 Study of Topical Radezolid for Treatment of Acne
NEW HAVEN, Conn., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT) a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, announced today that the company’s partner has initiated a Phase 2 clinical...
Nov 06, 2017 08:00 am ET
Melinta Therapeutics Announces Successful Completion of Merger
- New Nasdaq-Listed Melinta Therapeutics Will Begin Trading on November 6, 2017 under Ticker MLNT -

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.